CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¼Û½ÂÈÆ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ºÎÀÎÁ¾¾çÇÐ, ·Îº¿¼ö¼ú
  • Á÷ À§: ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
23 ÇØ¿Ü The expression of p 16 (INK 4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins.  
22 ÇØ¿Ü The relationship between cytokines and HPV 16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.  
21 ÇØ¿Ü The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins.  
20 ±¹³» Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures  
19 ÇØ¿Ü Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix  
18 ÇØ¿Ü Persistent HPV infection after conization in patients with negative margins  
17 ±¹³» 1±â ¹× 2±â Àڱ󻸷¾Ï 59¿¹ÀÇ ÀÓ»óº´¸®ÇÐÀû Ư¡ ¹× ¿¹ÈÄ ÀÎÀÚ¿¡ °üÇÑ ¿¬±¸  
16 ±¹³» Àӻ󿬱¸: ÀڱðæºÎ ¼¼Æ÷ °Ë»ç»ó ÀÌ»ó ¼±¼¼Æ÷¿¡¼­ °íµî±Þ º´º¯ÀÇ À§Çè ÀÎÀÚ  
15 ±¹³» ÃÖ±Ù 15³â°£ Çѱ¹¿¡¼­ÀÇ Àڱ󻸷¾ÏÀÇ »ýÁ¸À² ¹× Ä¡·á ¹æ¹ýÀÇ º¯È­  
14 ±¹³» ÀڱðæºÎ¼±¾Ï 80¿¹ÀÇ ÀÓ»óº´¸®ÇÐÀû Ư¼º ¹× ¿¹ÈÄ ÀÎÀÚ¿¡ °üÇÑ ¿¬±¸  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729